Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel ImmunoSpheres
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young Jun | - |
dc.contributor.author | Cho, Young-Ho | - |
dc.contributor.author | Min, Junhong | - |
dc.contributor.author | Han, Sae-Won | - |
dc.date.accessioned | 2021-08-12T01:40:23Z | - |
dc.date.available | 2021-08-12T01:40:23Z | - |
dc.date.issued | 2021-01-19 | - |
dc.identifier.issn | 0003-2700 | - |
dc.identifier.issn | 1520-6882 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/48069 | - |
dc.description.abstract | Here, we present chemically stable and instantly degradable (CSID) hydrogel immunospheres for the isolation of circulating tumor cells (CTCs) and circulating tumor exosomes (CTXs). The CSID hydrogels, which are prepared by the hybridization of alginate and poly(vinyl alcohol), show an equilibrium swelling ratio (ESR) of at pH 7, with a highly stable pH-responsive property. The present hybrid hydrogel is not easily disassociated in the biological buffers, thus being suitable for use in "liquid biopsy", requiring a multistep, long-term incubation process with biological samples. Also, it is gradually degraded by the action of chelating agents; effortless retrieval of the circulating markers has been achieved. Then, we modified the CSID hydrogel spheres with the anti-EpCAM antibody ("C-CSID ImmunoSpheres") and the anti-CD63 antibody ("E-CSID ImmunoSpheres") to isolate two promising circulating markers in liquid biopsy: CTCs and CTXs. The immunospheres' capabilities for marker isolation and retrieval were confirmed by a fluorescence image, where the spheres successfully isolate and effortlessly retrieve the target circulating markers. Lastly, we applied the CSID hydrogel immunospheres to five blood samples from colorectal cancer patients and retrieved average 10.8 +/- 5.9 CTCs/mL and average 96.5 X 10(6) CTXs/mL. The present CSID hydrogel immunospheres represent a simple, versatile, and time-efficient assay platform for liquid biopsy in the practical setting, enabling us to gain a better understanding of disease-related circulating markers. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Circulating Tumor Marker Isolation with the Chemically Stable and Instantly Degradable (CSID) Hydrogel ImmunoSpheres | - |
dc.type | Article | - |
dc.identifier.doi | 10.1021/acs.analchem.0c04152 | - |
dc.identifier.bibliographicCitation | ANALYTICAL CHEMISTRY, v.93, no.2, pp 1100 - 1109 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000612336200056 | - |
dc.identifier.scopusid | 2-s2.0-85099014878 | - |
dc.citation.endPage | 1109 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 1100 | - |
dc.citation.title | ANALYTICAL CHEMISTRY | - |
dc.citation.volume | 93 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | METASTATIC BREAST-CANCER | - |
dc.subject.keywordPlus | EXTRACELLULAR VESICLES | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | EXOSOME ISOLATION | - |
dc.subject.keywordPlus | BRAF MUTATIONS | - |
dc.subject.keywordPlus | LIQUID BIOPSY | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordPlus | RELEASE | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordPlus | CAPTURE | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.